Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 3/2017

Open Access 01-03-2017 | General Gynecology

Experience with oral emergency contraception since the OTC switch in Germany

Authors: Marion Kiechle, Miriam Neuenfeldt

Published in: Archives of Gynecology and Obstetrics | Issue 3/2017

Login to get access

Abstract

Purpose

In March 2015, the oral emergency contraceptives levonorgestrel (LNG) and ulipristal acetate (UPA) were released from prescription-only status in Germany. The main research question is to analyse whether the OTC status of oral emergency contraceptives has an influence on the patterns of use.

Methods

All information is based on searches for public domain sources on emergency contraception. Searches were made for scientific publications, statistics, and surveys.

Results

Due to additional active ingredient properties, UPA is superior to LNG in terms of ovulation-inhibiting effect. Since the OTC switch, demand for oral emergency contraceptives has risen by almost 50%, especially at weekends when sexual encounters and thus contraceptive failures are most frequent. However, the age distribution of the users has not changed as a result of the OTC switch. Doctors still play an important role in advising on emergency contraception after the removal of the prescription-only requirement. Pregnancies despite emergency contraception are terminated in more than half of the cases. In federal states with higher rates of use of the morning-after pill, fewer terminations of pregnancy were performed.

Conclusion

As a result of the OTC switch, more women and girls use the morning-after pill after unprotected intercourse and the time between unprotected intercourse and taking the oral emergency contraceptive decreases. This is of great advantage in terms of the mechanism of action. UPA is used more frequently than LNG. Only half of all people aged between 16 and 39 years in Germany are aware of the morning-after pill and 94% of women who had a pregnancy terminated in 2015 did not use any emergency contraception after the unprotected intercourse. In the population, there is still a great need for information and education on contraception and emergency contraception.
Literature
1.
go back to reference Gemzell-Danielsson K, Berger C, Lalitkumar PG (2014) ISGE statement on emergency contraception—mechanisms of action of oral emergency contraception. Gynecol Endocrinol 30:685–687CrossRefPubMed Gemzell-Danielsson K, Berger C, Lalitkumar PG (2014) ISGE statement on emergency contraception—mechanisms of action of oral emergency contraception. Gynecol Endocrinol 30:685–687CrossRefPubMed
2.
go back to reference Croxatto HB, Brache V, Paveza M et al (2004) Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75 mg-dose given on the days preceding ovulation. Contraception 70:442–450CrossRefPubMed Croxatto HB, Brache V, Paveza M et al (2004) Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75 mg-dose given on the days preceding ovulation. Contraception 70:442–450CrossRefPubMed
3.
go back to reference Brache V, Cochon L, Jesam C et al (2010) Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicle rupture. Hum Reprod 25:2256–2263CrossRefPubMed Brache V, Cochon L, Jesam C et al (2010) Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicle rupture. Hum Reprod 25:2256–2263CrossRefPubMed
4.
go back to reference Brache V, Cochon L, Deniaud M, Croxatto HB (2013) Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 88:611–618CrossRefPubMed Brache V, Cochon L, Deniaud M, Croxatto HB (2013) Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 88:611–618CrossRefPubMed
5.
go back to reference Trussel J, Rodríguez G, Ellertson C (1998) New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 57:363–369CrossRef Trussel J, Rodríguez G, Ellertson C (1998) New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 57:363–369CrossRef
6.
go back to reference Baird DD, McConnaughey R, Weinberg CR et al (1995) Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Epidemiology 6:547–550CrossRefPubMed Baird DD, McConnaughey R, Weinberg CR et al (1995) Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Epidemiology 6:547–550CrossRefPubMed
7.
9.
go back to reference Nallasamy S, Kim J, Sitruk-Ware R, Bagchi M, Bagchi I (2012) Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary. Redrod Sci 20:371–381CrossRef Nallasamy S, Kim J, Sitruk-Ware R, Bagchi M, Bagchi I (2012) Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary. Redrod Sci 20:371–381CrossRef
10.
go back to reference Bouchard P (2014) Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 30:683–684CrossRefPubMed Bouchard P (2014) Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 30:683–684CrossRefPubMed
11.
go back to reference Sales figures emergency contraceptive pills 2014/2015: data: IMS HEALTH GmbH & Co. OHG: Sell Out March–December 2014 vs Sell Out March–December 2015 Sales figures emergency contraceptive pills 2014/2015: data: IMS HEALTH GmbH & Co. OHG: Sell Out March–December 2014 vs Sell Out March–December 2015
12.
go back to reference Rabe T, Albring C, Arbeitskreis “Postkoitale Kontrazeption” (2013) Notfallkontrazeption—ein Update—Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands der Frauenärzte (BVF) e.V. 6.2.2013; Frauenarzt 54:108–114 Rabe T, Albring C, Arbeitskreis “Postkoitale Kontrazeption” (2013) Notfallkontrazeption—ein Update—Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands der Frauenärzte (BVF) e.V. 6.2.2013; Frauenarzt 54:108–114
15.
go back to reference Durex-Study (2011) Sexual behavior of Germans: 69% of all women are regularly sexual active Durex-Study (2011) Sexual behavior of Germans: 69% of all women are regularly sexual active
17.
go back to reference Survey by EMNID (2015) Most frequent Sex—TNS EMNID (1000 interviewees, 16–39 years). Sex at the weekend is related to sex on Friday until Sunday, December 2015 Survey by EMNID (2015) Most frequent Sex—TNS EMNID (1000 interviewees, 16–39 years). Sex at the weekend is related to sex on Friday until Sunday, December 2015
18.
go back to reference Data at the time of prescription-only status—Medimed prescriber study 1. Half-year 2010, prescribing frequency of the morning-after pill in doctors’ practices on the basis of 14,223 prescriptions Data at the time of prescription-only status—Medimed prescriber study 1. Half-year 2010, prescribing frequency of the morning-after pill in doctors’ practices on the basis of 14,223 prescriptions
19.
go back to reference Data at the time of the OTC status—IMS HEALTH GmbH & Co. OHG, day-of-the-week-study on the morning-after pill, October–December 2015 Data at the time of the OTC status—IMS HEALTH GmbH & Co. OHG, day-of-the-week-study on the morning-after pill, October–December 2015
20.
go back to reference Data at the time of prescription-only status: study on the age distribution of the morning-after pill users, 1. Half-year 2010, Medimed GmbH Data at the time of prescription-only status: study on the age distribution of the morning-after pill users, 1. Half-year 2010, Medimed GmbH
21.
go back to reference Data at the time of the OTC status: Market research covering 1018 pharmacies, July/August 2015, HRA Pharma Deutschland GmbH Data at the time of the OTC status: Market research covering 1018 pharmacies, July/August 2015, HRA Pharma Deutschland GmbH
22.
go back to reference EU survey on EC perception 2012, BVA Healthcare EU survey on EC perception 2012, BVA Healthcare
24.
go back to reference Analysis of prescriptions for oral emergency contraceptives: IMS HEALTH GmbH & Co. OHG: Prescriber data 2015 Analysis of prescriptions for oral emergency contraceptives: IMS HEALTH GmbH & Co. OHG: Prescriber data 2015
25.
go back to reference Gainer E, Blum J, Toverud E-L et al (2003) Bringing emergency contraception over the counter: experiences of nonprescription users in France, Norway, Sweden and Portugal. Contraception 68:117–124CrossRefPubMed Gainer E, Blum J, Toverud E-L et al (2003) Bringing emergency contraception over the counter: experiences of nonprescription users in France, Norway, Sweden and Portugal. Contraception 68:117–124CrossRefPubMed
27.
go back to reference Glasier AF, Cameron ST, Fine PM et al (2010) Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 375:555–562CrossRefPubMed Glasier AF, Cameron ST, Fine PM et al (2010) Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 375:555–562CrossRefPubMed
28.
go back to reference Cheng L, Che Y, Gülmezoglu AM (2012) Interventions for emergency contraception (Review). Cochrane Library 8:1–110 Cheng L, Che Y, Gülmezoglu AM (2012) Interventions for emergency contraception (Review). Cochrane Library 8:1–110
29.
go back to reference Creinin MD, Schlaff W, Archer DF et al (2006) Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108:1089–1097CrossRefPubMedPubMedCentral Creinin MD, Schlaff W, Archer DF et al (2006) Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108:1089–1097CrossRefPubMedPubMedCentral
31.
go back to reference Periodic safety update report ellaOne® No. 9, Mai 2015. Annual safety update report to ellaOne®, submitted to the European Medicines Agency Periodic safety update report ellaOne® No. 9, Mai 2015. Annual safety update report to ellaOne®, submitted to the European Medicines Agency
32.
go back to reference Levy DP, Jäger M, Kapp N, Abitbol J-L (2014) Ulipristal acetate for emergency contraception: post-marketing experience after use by more than 1 million women. Contraception 89:431–433CrossRefPubMed Levy DP, Jäger M, Kapp N, Abitbol J-L (2014) Ulipristal acetate for emergency contraception: post-marketing experience after use by more than 1 million women. Contraception 89:431–433CrossRefPubMed
33.
go back to reference Singh S, Sedgh G, Hussain R (2010) Unintended pregnancy: Worldwide levels, trends and outcomes. Stud Fam Plan 41:241–250CrossRef Singh S, Sedgh G, Hussain R (2010) Unintended pregnancy: Worldwide levels, trends and outcomes. Stud Fam Plan 41:241–250CrossRef
37.
go back to reference Survey by EMNID: Representative EMNID survey on knowledge of the morning-after pill—TNS EMNID (1000 interviewees, 16–39 years), on behalf of HRA-Pharma, August 2015 Survey by EMNID: Representative EMNID survey on knowledge of the morning-after pill—TNS EMNID (1000 interviewees, 16–39 years), on behalf of HRA-Pharma, August 2015
Metadata
Title
Experience with oral emergency contraception since the OTC switch in Germany
Authors
Marion Kiechle
Miriam Neuenfeldt
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 3/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-016-4253-0

Other articles of this Issue 3/2017

Archives of Gynecology and Obstetrics 3/2017 Go to the issue